Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Chondrosarcoma-associated gene 1 protein (CSAG1) is a tumor antigen expressed in chondrosarcomas and certain normal tissues such as testis[1]. CSAG1 localizes to the centrosome and plays a critical role in maintaining the integrity of the mitotic spindle pole by constraining the pericentriolar material, thereby ensuring proper chromosome segregation[2][3]. Its loss leads to abnormal spindle pole formation (multipolar mitosis), especially in cells with defective p53 function, suggesting a specific vulnerability in cancer cells lacking p53. CSAG1 may thus represent a candidate for targeted therapy in select cancers[2][3]. There is no current evidence for approved drugs directly targeting CSAG1, nor is it an established clinical biomarker or therapeutic target as of now.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Chondrosarcoma-associated gene 1 protein (CSAG1).